Vivos Therapeutics Past Earnings Performance
Past criteria checks 0/6
Vivos Therapeutics's earnings have been declining at an average annual rate of -2.2%, while the Healthcare industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 3.3% per year.
Key information
-2.2%
Earnings growth rate
19.6%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 3.3% |
| Return on equity | -164.0% |
| Net Margin | -86.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar
Dec 27
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely
Nov 12Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Sep 10It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Apr 25It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be
May 21Vivos Therapeutics: First Take After The Broad Market Sell-Off
Mar 06Revenue & Expenses Breakdown
How Vivos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 15 | -13 | 21 | 0 |
| 30 Jun 24 | 14 | -12 | 21 | 0 |
| 31 Mar 24 | 13 | -16 | 23 | 0 |
| 31 Dec 23 | 14 | -14 | 25 | 0 |
| 30 Sep 23 | 15 | -15 | 27 | 0 |
| 30 Jun 23 | 15 | -19 | 29 | 0 |
| 31 Mar 23 | 16 | -20 | 32 | 0 |
| 31 Dec 22 | 16 | -24 | 34 | 0 |
| 30 Sep 22 | 16 | -25 | 36 | 0 |
| 30 Jun 22 | 17 | -25 | 36 | 0 |
| 31 Mar 22 | 17 | -22 | 34 | 0 |
| 31 Dec 21 | 17 | -20 | 31 | 0 |
| 30 Sep 21 | 16 | -24 | 27 | 0 |
| 30 Jun 21 | 15 | -21 | 23 | 0 |
| 31 Mar 21 | 13 | -19 | 20 | 0 |
| 31 Dec 20 | 13 | -18 | 18 | 0 |
| 30 Sep 20 | 13 | -9 | 18 | 0 |
| 30 Jun 20 | 13 | -11 | 19 | 0 |
| 31 Mar 20 | 12 | -12 | 19 | 0 |
| 31 Dec 19 | 11 | -12 | 18 | 0 |
| 31 Dec 18 | 4 | -9 | 10 | 0 |
Quality Earnings: VVOS is currently unprofitable.
Growing Profit Margin: VVOS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VVOS is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare VVOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VVOS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.4%).
Return on Equity
High ROE: VVOS has a negative Return on Equity (-163.97%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 08:33 |
| End of Day Share Price | 2025/01/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivos Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Edward Woo | Ascendiant Capital Markets LLC |
| Lucas Ward | Ascendiant Capital Markets LLC |